(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 43.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Axsome Therapeutics's revenue in 2025 is $495,033,000.On average, 22 Wall Street analysts forecast AXSM's revenue for 2025 to be $31,519,276,234, with the lowest AXSM revenue forecast at $29,395,967,962, and the highest AXSM revenue forecast at $33,581,205,677. On average, 22 Wall Street analysts forecast AXSM's revenue for 2026 to be $48,717,823,728, with the lowest AXSM revenue forecast at $38,022,438,020, and the highest AXSM revenue forecast at $57,087,301,128.
In 2027, AXSM is forecast to generate $74,103,708,195 in revenue, with the lowest revenue forecast at $56,538,384,771 and the highest revenue forecast at $97,806,914,520.